Shopping Cart (Login required)

Biotage Introduces New Isolera™ FLASH Purification System for Faster Separations

29 May 2008


News release
Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com


Biotage Introduces New Isolera™ FLASH Purification System for Faster Separations

(May 28, 2008) Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announces the introduction of the new Isolera compact FLASH purification system. This unique new instrument enables chemists to easily achieve better separations in significantly shorter purification run-times, while new features result in maximum purity and yield.

The high-performance Isolera system from Biotage contains intelligent features which allow users to maximize time and resources. The advanced TLC-to-gradient feature automatically creates elution gradients and suggests cartridge and sample size. Compounds can be collected on two separate wavelengths using a variable wavelength detector option, resulting in increased compound recovery and cleaner fractions.

With the Isolera FLASH purification system, up to four solvents can be used in a single gradient to easily purify samples with diverse polarity. A third co-solvent can be isocratically pumped into the binary gradient, maintaining compound solubility and eliminating the over-pressure issues that can be caused by precipitating compounds. Users have full control over sample purification conditions, as a full range of editing options is available, including gradient, flow rate, collection volume and fraction wavelengths and modes.

Providing default methods built around both TLC conditions and SNAP cartridge sizes, the new Isolera system enables chemists to quickly purify samples. Samples with poor or no UV chromophore can be purified by connecting an external detector such as refractive index or evaporative light scattering detector (ELSD) to the system. Isolera fractionates compounds using the auxiliary detector’s signal while simultaneously monitoring the Isolera UV signal.

The Isolera system from Biotage comes complete with SNAP cartridges and everything required to begin purifying samples quickly.

For more information on the Isolera FLASH purification system, please call 434-979-2319 (press 3), email product_info@biotage.com, or visit www.biotage.com


-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the world’s top 30 pharmaceutical companies, the world’s top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as \"believe,\" \"expect,\" \"intend,\" and \"should,\" among others. These forward-looking statements are based on Biotage’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a \"safe harbor\" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage’s products (including seasonal fluctuations), difficulties in successfully adapting the Company’s products to integrated solutions and producing such products, and the Company’s ability to identify and develop new products and to differentiate its products from competitors.